 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 June 1998 | Volume 128 Issue 11 | Pages 906-911
Background: Drug resistance of HIV-1 is an obstacle to the long-term efficacy of antiretroviral therapy.
Objective: To characterize reverse transcriptase and protease genes of multidrug-resistant HIV-1 isolates.
Design: Descriptive case series.
Setting: Academic medical center.
Patients: Four consecutive patients with HIV-1 infection were selected because they had previously received many antiretroviral drugs and had not achieved plasma HIV-1 RNA suppression despite treatment with several three-drug combinations.
Measurements: Reverse transcriptase sequencing, protease sequencing, and drug susceptibility testing of HIV-1.
Results: Isolates of HIV-1 from the four patients shared seven protease mutations and eight reverse transcriptase mutations. These mutations were present in biological clones and at three time points in three of the patients. Susceptibility testing showed high-level resistance (30-fold to >100-fold) to zidovudine, lamivudine, saquinavir, indinavir, and nelfinavir and lower-level resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine.
Conclusions: Simultaneous resistance to almost all available antiretroviral drugs may occur in HIV-1. The concordance and persistence of mutations in drug-resistant HIV-1 isolates suggest that some combinations of reverse transcriptase and protease mutations give the virus a selective advantage in the presence of various drug combinations.
Author and Article Information
From Stanford University Medical Center, Stanford, California. For current author addresses, see end of text.
BRIEF COMMUNICATION
Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients
Acknowledgments: Patient 1 was enrolled in the National Institutes of Health AIDS Clinical Trials Group Protocol 019 between 1987 and 1990. The authors thank Darcy Levee (Stanford University) for assistance with DNA sequencing; Muoi Loi (Stanford University) for assistance with drug susceptibility testing; and Andy Zolopa, MD, for critical review of the manuscript.
Grant Support: In part by National Institutes of Health grant AI27666 and a gift from the J.M. Kaplan Fund (New York, New York).
Requests for Reprints: Robert W. Shafer, MD, Division of Infectious Diseases, Room S-156, Stanford University Medical Center, Stanford, CA 94305; e-mail, rshafer@cmgm.stanford.edu.
Current Author Addresses: Drs. Shafer, Winters, Palmer, and Merigan: Division of Infectious Diseases, Stanford University Medical Center, Stanford, CA 94305.
This article has been cited by other articles:
|
|
 |
|
  G. N. Nikolenko, S. Palmer, F. Maldarelli, J. W. Mellors, J. M. Coffin, and V. K. Pathak Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision PNAS, February 8, 2005; 102(6): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palmer, M. Kearney, F. Maldarelli, E. K. Halvas, C. J. Bixby, H. Bazmi, D. Rock, J. Falloon, R. T. Davey Jr., R. L. Dewar, et al. Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis J. Clin. Microbiol., January 1, 2005; 43(1): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Greenberg and N. Cammack Resistance to enfuvirtide, the first HIV fusion inhibitor J. Antimicrob. Chemother., August 1, 2004; 54(2): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Clavel and A. J. Hance HIV Drug Resistance N. Engl. J. Med., March 4, 2004; 350(10): 1023 - 1035. [Full Text] [PDF]
|
|
|
|
|
|
S. Palmer, A. P. Wiegand, F. Maldarelli, H. Bazmi, J. M. Mican, M. Polis, R. L. Dewar, A. Planta, S. Liu, J. A. Metcalf, et al. New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma J. Clin. Microbiol., October 1, 2003; 41(10): 4531 - 4536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Wu, C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments J. Virol., April 15, 2003; 77(8): 4836 - 4847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watkins, W. Resch, D. Irlbeck, and R. Swanstrom Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors Antimicrob. Agents Chemother., February 1, 2003; 47(2): 759 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Spira, M. A. Wainberg, H. Loemba, D. Turner, and B. G. Brenner Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance J. Antimicrob. Chemother., February 1, 2003; 51(2): 229 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Sayer, S. Land, L. Gizzarelli, M. French, G. Hales, S. Emery, F. T. Christiansen, and E. M. Dax Quality Assessment Program for Genotypic Antiretroviral Testing Improves Detection of Drug Resistance Mutations J. Clin. Microbiol., January 1, 2003; 41(1): 227 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Dunbar, D. Madigan, L. A. Grohskopf, D. Revere, J. Woodward, J. Minstrell, P. A. Frick, J. M. Simoni, and T. M. Hooton A Two-way Messaging System to Enhance Antiretroviral Adherence J. Am. Med. Inform. Assoc., January 1, 2003; 10(1): 11 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Loemba, B. Brenner, M. A. Parniak, S. Ma'ayan, B. Spira, D. Moisi, M. Oliveira, M. Detorio, and M. A. Wainberg Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2087 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kantor, W. J. Fessel, A. R. Zolopa, D. Israelski, N. Shulman, J. G. Montoya, M. Harbour, J. M. Schapiro, and R. W. Shafer Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Plettenberg, D. Albrecht, T. Lorenzen, V. Paech, H. Petersen, T. Fenner, T. Meyer, R. Arndt, K. Hertogs, R. Pauwels, et al. Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens Sex. Transm. Inf., December 1, 2001; 77(6): 449 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Wilson, P. Bean, T. Robins, F. Graziano, and D. H. Persing Comparative Evaluation of Three Human Immunodeficiency Virus Genotyping Systems: the HIV-GenotypR Method, the HIV PRT GeneChip Assay, and the HIV-1 RT Line Probe Assay J. Clin. Microbiol., August 1, 2000; 38(8): 3022 - 3028. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Babudieri, A. Aceti, G. P. D'Offizi, S. Carbonara, and G. Starnini Directly Observed Therapy to Treat HIV Infection in Prisoners JAMA, July 12, 2000; 284(2): 179 - 180. [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Martínez, M. Cabana, M. Parera, A. Gutierrez, J. A. Esté, and B. Clotet A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1132 - 1139. [Abstract] [Full Text]
|
|
|
|
|
|
D. V. Havlir, N. S. Hellmann, C. J. Petropoulos, J. M. Whitcomb, A. C. Collier, M. S. Hirsch, P. Tebas, J.-P. Sommadossi, and D. D. Richman Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens JAMA, January 12, 2000; 283(2): 229 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ibáñez, B. Clotet, and M.-A. Martínez Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies J. Gen. Virol., January 1, 2000; 81(1): 85 - 95. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. W. Shafer, D. R. Jung, B. J. Betts, Y. Xi, and M. J. Gonzales Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database Nucleic Acids Res., January 1, 2000; 28(1): 346 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Zolopa, R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed Ann Intern Med, December 7, 1999; 131(11): 813 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Mayhew, J. D. Phillips, R. N. Greenberg, N. J. Birch, H. L. Elfordf, and V. S. Gallicchio In Vivo and In Vitro Comparison of the Short-Term Hematopoietic Toxicity Between Hydroxyurea and Trimidox or Didox, Novel Ribonucleotide Reductase Inhibitors with Potential Anti-HIV-1 Activity Stem Cells, November 1, 1999; 17(6): 345 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
D. Boden, A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, et al. HIV-1 Drug Resistance in Newly Infected Individuals JAMA, September 22, 1999; 282(12): 1135 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Pomerantz Primary HIV-1 Resistance: A New Phase in the Epidemic? JAMA, September 22, 1999; 282(12): 1177 - 1179. [Full Text] [PDF]
|
|
|
|
|
|
S. Palmer, R. W. Shafer, and T. C. Merigan Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2046 - 2050. [Abstract] [Full Text]
|
|
|
|
|
|
K. K. A. van Rompay, J. M. Cherrington, M. L. Marthas, P. D. Lamy, P. J. Dailey, D. R. Canfield, R. P. Tarara, N. Bischofberger, and N. C. Pedersen 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA Antimicrob. Agents Chemother., April 1, 1999; 43(4): 802 - 812. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. Rindfleisch and D. L. Brutlag Directions for Clinical Research and Genomic Research into the Next Decade: Implications for Informatics J. Am. Med. Inform. Assoc., September 1, 1998; 5(5): 404 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Cohen and A. S. Fauci Transmission of Multidrug-Resistant Human Immunodeficiency Virus -- The Wake-Up Call N. Engl. J. Med., July 30, 1998; 339(5): 341 - 343. [Full Text]
|
|
Article
